Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma

Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Moran, A, Ramakrishnan, S, Borg, C, Connolly, C, Couillard, S, Mwasuku, C, Pavord, I, Hinks, T, Lehtimaki, L
Μορφή:	Conference item
Γλώσσα:	English
Έκδοση:	European Respiratory Society 2020

Παρόμοια τεκμήρια

Blood eosinophil depletion with mepolizumab, benralizumab and prednisolone in eosinophilic asthma
ανά: Moran, AM, κ.ά.
Έκδοση: (2020)

Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
ανά: Shrimanker, R, κ.ά.
Έκδοση: (2017)

Mepolizumab and benralizumab in patients with severe asthma and a history of eosinophilic granulomatosis with polyangiitis
ανά: Charlene Desaintjean, κ.ά.
Έκδοση: (2024-03-01)

Glucocorticoids and mepolizumab in eosinophilic asthma.
ανά: Bel, E, κ.ά.
Έκδοση: (2014)

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
ανά: Andrea Portacci, κ.ά.
Έκδοση: (2023-10-01)

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
ανά: Bel, E, κ.ά.
Έκδοση: (2014)

Clinical and economic comparison of utilization of reslizumab, mepolizumab and benralizumab in the treatment of severe eosinophilic asthma
ανά: S. K. Zyryanov, κ.ά.
Έκδοση: (2020-12-01)

Mepolizumab in refractory eosinophilic asthma.
ανά: Pavord, I, κ.ά.
Έκδοση: (2010)

Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts
ανά: Arian Ghassemian, κ.ά.
Έκδοση: (2021-01-01)

Mepolizumab, quality of life, and severe eosinophilic asthma.
ανά: Pavord, I
Έκδοση: (2017)

Mepolizumab and exacerbations of refractory eosinophilic asthma.
ανά: Haldar, P, κ.ά.
Έκδοση: (2009)

Airway proteomics reveals broad residual anti-inflammatory effects of prednisolone in mepolizumab-treated asthma
ανά: Howell, I, κ.ά.
Έκδοση: (2024)

Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab
ανά: Erminia Ridolo, κ.ά.
Έκδοση: (2020-10-01)

Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months
ανά: Kayser MZ, κ.ά.
Έκδοση: (2021-07-01)

Mepolizumab treatment in patients with severe eosinophilic asthma.
ανά: Ortega, H, κ.ά.
Έκδοση: (2014)

Mepolizumab for eosinophilic COPD
ανά: Sciurba, F, κ.ά.
Έκδοση: (2018)

Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab
ανά: Osamu Matsuno, κ.ά.
Έκδοση: (2019-01-01)

Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma
ανά: Yancey, S, κ.ά.
Έκδοση: (2016)

Clinical usefulness of mepolizumab in severe eosinophilic asthma
ανά: Menzella F, κ.ά.
Έκδοση: (2016-06-01)

Reductions in Eosinophil Biomarkers by Benralizumab in Patients With Asthma
ανά: Mirhojjat Khorasanizadeh, κ.ά.
Έκδοση: (2017-07-01)

Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma
ανά: Gómez-Bastero Fernández A, κ.ά.
Έκδοση: (2022-05-01)

Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma.
ανά: Gunsoy, N, κ.ά.
Έκδοση: (2017)

Real-World clinical outcomes of asthma patients switched from reslizumab to mepolizumab or benralizumab
ανά: Laura J. Walsh, κ.ά.
Έκδοση: (2023-01-01)

Mepolizumab asthma treatment failure due to refractory airway eosinophilia, which responded to benralizumab
ανά: Alistair Cook, κ.ά.
Έκδοση: (2021-05-01)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
ανά: Howell, I, κ.ά.
Έκδοση: (2024)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
ανά: Imran Howell, κ.ά.
Έκδοση: (2024-07-01)

Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma
ανά: Stephen G. Noorduyn, κ.ά.
Έκδοση: (2021-12-01)

The clinical profile of benralizumab in the management of severe eosinophilic asthma
ανά: Francesco Menzella, κ.ά.
Έκδοση: (2016-12-01)

Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide
ανά: Couillard, S, κ.ά.
Έκδοση: (2021)

Asthma in pregnancy: An update
ανά: Couillard, S, κ.ά.
Έκδοση: (2020)

Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
ανά: Shrimanker, R, κ.ά.
Έκδοση: (2017)

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
ανά: Ortega, H, κ.ά.
Έκδοση: (2016)

Clinical outcomes with mepolizumab therapy in routine practice in the oxford cohort
ανά: Gittins, A, κ.ά.
Έκδοση: (2018)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
ανά: Steven W. Yancey, κ.ά.
Έκδοση: (2019-09-01)

Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab
ανά: Lisha Li, κ.ά.
Έκδοση: (2021-06-01)

Efficacy and safety of benralizumab in elderly patients with severe eosinophilic asthma
ανά: Kohei Somekawa, κ.ά.
Έκδοση: (2024-12-01)

Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial
ανά: Andrew Menzies-Gow, κ.ά.
Έκδοση: (2019-09-01)

Fractional exhaled nitric oxide and the peripheral blood eosinophil count as biomarkers of the response to mepolizumab in patients with severe eosinophilic asthma
ανά: Shrimanker, R, κ.ά.
Έκδοση: (2018)

Utility of adherence checks in patients with severe asthma eligible for biologics: a single centre retrospective analysis
ανά: Oliver, ME, κ.ά.
Έκδοση: (2021)

Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis
ανά: Carlos Martínez-Rivera, κ.ά.
Έκδοση: (2021-01-01)